Skip to main content
Voyageur Pharmaceuticals Ltd. logo

Voyageur Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · VM ISIN · CA92918C1014 TSXV Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2024-01-16 Capital/Financing Update
Country CA Canada
Listing TSXV VM

About Voyageur Pharmaceuticals Ltd.

https://voyageurpharmaceuticals.ca/

Voyageur Pharmaceuticals Ltd. develops and supplies contrast media products for medical imaging, including CT scans and fluoroscopy. The company operates using a vertically integrated "Earth to Bottle" strategy, controlling the entire supply chain from raw mineral acquisition to finished pharmaceutical product. Voyageur owns a significant, high-purity barium sulfate resource, positioning it as a secure and sustainable supplier of pharmaceutical-grade barium sulfate, the active ingredient in its commercialized contrast agents (e.g., SmoothX® and SmoothHD® series). This vertical control aims to ensure supply security and cost competitiveness, primarily targeting the North American market. The company is also actively developing iodine-based contrast media and V-Gas® Effervescent Granules to expand its portfolio of diagnostic imaging solutions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing a private placement financing by Voyageur Pharmaceuticals Ltd. It details the terms of the offering, use of proceeds, record date, and regulatory approvals required. There are no financial statements, earnings data, or management discussion of financial results. The content focuses on capital raising activities and financing terms. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing, not just a brief announcement or link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2024-01-16 English
News release - English.pdf
Regulatory Filings
2023-12-21 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing Voyageur Pharmaceuticals' international expansion through a sales and distribution alliance. It discusses strategic partnerships, product launches, business plans, and forward-looking statements. There are no financial statements, regulatory filings, or detailed financial data presented. The content is typical of a corporate announcement about business development and market expansion rather than a formal financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is also not a report publication announcement or certification. Given the nature of the content as a corporate news release about business activities and forward-looking plans, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2023-12-14 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CEO certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended August 31, 2023. It is primarily an officer certification letter rather than the interim report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is short (3040 characters) and contains no substantive financial data or analysis, only the certification statement. Therefore, the correct classification is Regulatory Filings (RNS).
2023-10-30 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate. It is a certification letter by the CFO regarding the review and fair presentation of the interim financial report and interim MD&A for the period ended August 31, 2023. The document does not contain actual financial statements or substantive financial data but is an officer certification related to interim filings. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (3024 characters), and it is clearly a certification, not the report itself.
2023-10-30 English
Interim MD&A - English.pdf
Management Reports Classification · 100% confidence The document is titled 'Management’s Discussion & Analysis for the Three and Nine Months Ended August 31, 2023' and contains detailed analysis of the company's financial position, operational results, financing activities, and outlook for the specified interim periods. It includes substantive financial data such as net loss, cash flows, financing transactions, and strategic plans. The presence of forward-looking statements and detailed financial and operational discussion aligns with the typical content of an MD&A report. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document fits the category of Management Reports (MDA).
2023-10-30 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.